WO2013044607A1 - 一种自体脂肪干细胞抗衰老效果的评价体系 - Google Patents

一种自体脂肪干细胞抗衰老效果的评价体系 Download PDF

Info

Publication number
WO2013044607A1
WO2013044607A1 PCT/CN2012/070995 CN2012070995W WO2013044607A1 WO 2013044607 A1 WO2013044607 A1 WO 2013044607A1 CN 2012070995 W CN2012070995 W CN 2012070995W WO 2013044607 A1 WO2013044607 A1 WO 2013044607A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
individual
adipose
concentration
cells
Prior art date
Application number
PCT/CN2012/070995
Other languages
English (en)
French (fr)
Inventor
曹卫
吕伟麟
张丽
张露亿
张炳强
Original Assignee
臻景生物技术(上海)有限公司
臻景生物技术(无锡)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 臻景生物技术(上海)有限公司, 臻景生物技术(无锡)有限公司 filed Critical 臻景生物技术(上海)有限公司
Publication of WO2013044607A1 publication Critical patent/WO2013044607A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Definitions

  • the invention relates to the field of biotechnology and regenerative medicine. Specifically, the present invention relates to an evaluation system for anti-aging effects of autologous adipose stem cells, and the system of the present invention can accurately, objectively and promptly evaluate the anti-aging effect of fat stem cells. Background technique
  • Aging is a functional degenerative change of tissues, organs, and cells that occurs with the growth of the human body and environmental influences. It shows that the functional activity of the body is progressively declining, the ability to adapt to the environment is gradually reduced, and the metabolic balance in the body is imbalanced, which leads to A series of aging symptoms such as old complexion, loose skin, increased wrinkles, fatigue, decreased mental and physical labor, and decreased sexual function. Since aging is a systemic tissue and organ function degradation, strategies for anti-aging and shaping should also consider improving function from an overall level.
  • Stem cells are a kind of self-replicating pluripotent cells that can differentiate into multiple functional cells under certain conditions. Stem cells can regenerate aging degenerative diseases of various tissues, organs and systems, normalize and rejuvenate their structure and function, and regulate the state of the body as a whole. It is a systemic, systematic and fundamental health care.
  • Adipose tissue is generally considered to be a storage energy and endocrine organ. It is a necessary tissue for soft tissue filling and liposuction treatment. Adipose tissue is abundant in the human body and easy to obtain. Adipose tissue contains a variety of progenitor cells and can be differentiated into a variety of lineages, including adipocytes, adipose-derived stem cells (ADSCs), vascular endothelial cells, fibroblasts, macrophages, and extracellular matrices. Fat dry Cells (adipose-derived stem cells, ADSCs) are stem cells with multipotential differentiation potential.
  • ADSCs adipose-derived stem cells
  • ADSCs stably proliferate in vitro and have a low mortality rate. They have multi-directional differentiation potential in vitro and in vivo, and can be applied to adipocytes, chondrocytes, myocytes, osteoblasts, nerve cells, glial cells and islets under different inducing factors. Cells differentiate and secrete a variety of pro-angiogenic and anti-apoptotic factors.
  • Adipose-derived stem cells have a wide range of sources, are easy to obtain, have little damage to the body, have large reserves in the body, and can acquire a large number of stem cells in a small amount of tissue, and are suitable for autologous transplantation and large-scale culture. Therefore, adipose stem cells have gradually become one of the research hotspots in recent years. It provides new ideas for the treatment of a range of diseases.
  • Adipose-derived stem cells have important regulatory functions on metabolism and anti-aging.
  • Adipose-derived stem cells care and treatment can improve the body's metabolism of various lipoproteins, such as lowering total blood cholesterol concentration, improving body's glucose metabolism, and lowering blood sugar. Level, lower weight and other functions.
  • An object of the present invention is to provide a simple and/or efficient evaluation system for the anti-aging effect of autologous adipose stem cells.
  • the present invention provides an evaluation method for anti-aging of adipose stem cells.
  • a serological test is performed after a period of end of reinfusion, and the serological test includes detecting one selected from the group or Multiple indicators:
  • Vitamin D high density lipoprotein, low density lipoprotein, thyroid stimulating hormone, testosterone, estradiol.
  • Ral is the concentration of vitamin D in the serum after the individual is returned
  • RaO is the concentration of vitamin D before the end of the return
  • Rbl is the concentration of high-density lipoprotein in the serum after individual reinfusion
  • RbO is the concentration of high-density lipoprotein before the end of reinfusion
  • RcO is the low-density lipoprotein concentration before the end of the reinfusion
  • Rcl is the low-density lipoprotein concentration in the serum after the individual is reinfused
  • RdO is the concentration of thyroid stimulating hormone before the end of the reinfusion
  • Rdl is the concentration of thyroid stimulating hormone in the serum after the individual is returned
  • Rel is the concentration of testosterone in the serum after the individual is reinfused, and ReO is the concentration of testosterone before the end of the return;
  • Rfl is the concentration of estradiol in the serum after the individual is reinfused
  • RfO is the concentration of estradiol before the end of the return
  • the indicators when at least one of the indicators is effective, it indicates that the adipose stem cells have an anti-aging effect in the individual.
  • the dried stem cells when 2, 3 and 4 of the indicators are effective, produce an anti-aging effect in the individual.
  • the period of time is ⁇ 1 month.
  • the period of time is from 2 to 6 months, preferably 3 months.
  • the returned adipose stem cells are adipose stem cells cultured for 0-90 days. In another preferred embodiment, the returned adipose stem cells are adipose stem cells cultured for 30 days.
  • the adipose stem cell is an autologous adipose stem cell.
  • Ra ⁇ 10% it is suggested that the returned adipose stem cells have an anti-aging effect in the individual.
  • Ra ⁇ 20% it is suggested that the returned adipose stem cells have an anti-aging effect in the individual.
  • the returned adipose stem cells have one or more of the following characteristics:
  • more than 99% of the cells have the surface antigen CD29.
  • more than 95% of the cells have the surface antigen CD73. In another preferred embodiment, more than 95% of the cells have a surface antigen CD49d
  • more than 95% of the cells have the surface antigen CD90.
  • the adipose stem cell further has the following characteristics:
  • less than 3% of the cells have a surface antigen CD34
  • 0% of the cells have the surface antigen CD45.
  • Fig. 1 shows the results of analysis of surface antigen-labeled expression of the prepared SVF by flow cytometry.
  • Figure 2 shows the results of analysis of surface antigen-labeled expression of cultured adipose-derived stem cell population by flow cytometry.
  • Figure 3 shows the ability of isolated and cultured adipose-derived stem cells to differentiate into fat; wherein, Figure 3A shows that adipose-derived stem cells can produce lipids under the action of an adipogenic inducer, and a large amount of red lipid droplets can be produced in the cytoplasm;
  • Fig. 3B is a negative control of the adipogenic experiment, in which the adipose stem cells are not self-generating into lipids without the action of an adipogenic inducer.
  • Figure 4 shows the ability of isolated and cultured adipose-derived stem cells to differentiate into bone; wherein, Figure 4A shows that adipose-derived stem cells are stained with alizarin red under the action of an osteogenic inducer, and red calcified matrix deposition is observed in the cytoplasm;
  • Figure 4B shows a negative control of the osteogenic experiment in which adipose stem cells are not capable of spontaneous osteogenesis without the effect of an osteogenic inducer.
  • Figure 5 shows a subject who returned to adipose stem cells with a significant increase in the concentration of vitamin D in the blood.
  • Figure 6 shows the concentration of high-density lipoprotein (HDL) in subjects who returned to adipose-derived stem cells. Rise.
  • HDL high-density lipoprotein
  • Figure 7 shows that subjects who returned to adipose-derived stem cells showed a significant decrease in the concentration of low-density lipoprotein (LDL).
  • LDL low-density lipoprotein
  • Figure 8 shows that male subjects after adipose-derived stem cell reinfusion showed a significant increase in serum testosterone concentrations.
  • Figure 9 shows a female subject after adipose-derived stem cell reinfusion with a significant increase in the concentration of estradiol in the serum.
  • Figure 10 shows subjects who returned to adipose-derived stem cells with a significant decrease in the concentration of thyroid-stimulating hormone in their serum.
  • the inventors have extensively and intensively studied and unexpectedly found that among a large number of serological indicators available for examination, vitamin D, high-density lipoprotein, low-density lipoprotein, thyroid-stimulating hormone, testosterone (male), and female two
  • the change in the content of the alcohol (female) can be used as an effective index for evaluating the anti-aging effect of the autologous adipose stem cells, and when at least one of the indicators is effective, it indicates that the adipose stem cells have an anti-aging effect in the individual.
  • concentrations of cholesterol, blood glucose, total lipoprotein, etc. cannot be used as an indicator of the effectiveness of the evaluation of the anti-aging effects of adipose-derived stem cells.
  • the evaluation system of the present invention can objectively evaluate the anti-aging effect of adipose stem cells, and has the advantages of being fast, accurate, and economical. The present invention has been completed on this basis.
  • Autologous fat is an excellent source of plastic and anti-aging treatments.
  • Adipose tissue materials can be derived from the waist, hips, abdomen, thighs, upper arms and other parts.
  • One skilled in the art can obtain autologous adipose tissue using a general technical method including, but not limited to, aspiration, surgical separation, and the like.
  • Interstitial vascular debris (SVF) is an excellent source of plastic and anti-aging treatments.
  • Adipose tissue materials can be derived from the waist, hips, abdomen, thighs, upper arms and other parts.
  • One skilled in the art can obtain autologous adipose tissue using a general technical method including, but not limited to, aspiration, surgical separation, and the like.
  • Interstitial vascular debris (SVF) Interstitial vascular debris
  • SVF is the most important component of stem cell-assisted fat transplantation.
  • the cell cluster formed by a mixture of various cells isolated from adipose tissue by collagenase digestion is called interstitial blood vessel debris.
  • Interstitial vascular debris is rich in mesenchymal cells, which can differentiate into multiple lineage cells. It is the ideal seed cell for regenerative medicine and tissue engineering.
  • separating the SVF may include the following steps (but not limited to):
  • the liposuction fat was washed twice with PBS, then digested with collagenase for 30 min at 37 ° C, and the digestion was terminated with DMEM containing 10% fetal bovine serum. After 1200 g of centrifugation for 10 min, high-density SVF fragments were obtained. Among them are mainly interstitial cells, vascular endothelial cells and parietal cells. In addition, SVF also includes some blood vessel-derived cells, such as white blood cells and red blood cells, which have synergistic effects between various cells. Adipose stem cell
  • Adipose stem cells As used herein, the terms “adipose stem cells”, “adipose stem cells of the invention”, or “dry cells of the invention” are used interchangeably and refer to stem cells isolated from adipose tissue.
  • Adipose-derived stem cells are stem cells with multi-directional differentiation potential isolated from adipose tissue. ADSCs can stably proliferate in vitro and have a low mortality rate. It is easy to obtain, has a large amount of reserves in the body, is suitable for large-scale culture, has small damage to the body, is widely used, and is suitable for autologous transplantation.
  • the raw material of the adipose tissue or fat is not particularly limited, and may be an adipose tissue derived from any part of an animal or a human, preferably a human adipose tissue.
  • the adipose tissue may be a tissue of a part of the waist, the buttocks, the abdomen, the thigh, the upper arm, and the like.
  • the adipose stem cell population has a variety of specific antigens and receptors, mainly D29, CD73, CD49d,
  • CD34 antigen is a highly glycosylated type I transmembrane protein that is selectively expressed on human hematopoietic stem (HSC), progenitor (PC) and vascular endothelial (EC) surfaces and is a negative indicator of adipose stem cells.
  • HSC human hematopoietic stem
  • PC progenitor
  • EC vascular endothelial
  • the proportion of adipose stem cells with CD34 in total stem cells is preferably ⁇ 5%, more preferably ⁇ 3%.
  • CD45 is present on the surface of all hematopoietic cells, including hematopoietic stem cells and osteoclasts, and is a negative indicator of adipose stem cells.
  • the proportion of adipose stem cells with CD45 in total stem cells is preferably ⁇ 0.1%, and more preferably, 0%.
  • CD29, CD73, CD90, CD49d, etc. are mainly present on the surface of adipose-derived mesenchymal stem cells.
  • the proportion of adipose stem cells with CD29 in total stem cells is preferably ⁇ 95%, more preferably ⁇ 97%, and most preferably ⁇ 99%.
  • the proportion of adipose stem cells with CD73 in total stem cells is preferably ⁇ 80%, more preferably ⁇ 85%, and most preferably ⁇ 88%.
  • the proportion of adipose stem cells with CD90 in total stem cells is preferably ⁇ 75%, more preferably ⁇ 78%, and most preferably ⁇ 80%.
  • the proportion of adipose stem cells with CD49d in total stem cells is preferably ⁇ 90%, more preferably ⁇ 95%, optimally ⁇ 99%.
  • One skilled in the art can use a general method to detect the purity and degree of differentiation of adipose stem cells, such as flow cytometry.
  • different specific and targeted specific antibodies are added, and the antibody may be a complete monoclonal or polyclonal antibody, or may be an immunologically active antibody fragment, such as a Fab' or (Fab) 2 fragment; an antibody heavy chain; Antibody light chain; genetically engineered single chain Fv molecule; or chimeric antibody, such as an antibody that has murine antibody binding specificity but still retains antibody portions from humans.
  • the antibody is added to the antigen on the cell surface for a certain period of time, and the cells are automatically analyzed and sorted by flow cytometry.
  • adipose stem cells have multi-directional differentiation ability, differentiation of adipose-derived stem cells under certain conditions can obtain differentiated cells with specific functions.
  • a preferred method of induction is to add dexamethasone to the culture.
  • dexamethasone There are mainly three kinds of inducers containing dexamethasone: 1. Dexamethasone plus 1-methyl-3-isobutylxanthine (IBMX), 2. Dexamethasone plus insulin, 3. Dexamethasone plus armor New (indomethacin, indomethacin), 1-methyl-3-isobutylxanthine and insulin.
  • Low concentration of dexamethasone is one of the essential components of mesenchymal stem cells cultured in serum-free or low serum, which can promote the rapid proliferation of mesenchymal stem cells in vitro. Higher concentrations of dexamethasone can induce mesenchymal stem cells to fat. Cell Differentiation. Those skilled in the art can use common methods and dyes (such as Oil Red, Sudan Red 5B and Solvent Red 27, etc.) to detect adipogenic fat cells. A preferred dye is Oil Red (O), i.e., Oil Red 0.
  • oil red O is 1-[ 2,5-dimethyl-4-(2,5-dimethylphenylazo)phenylazo] -2 naphthol, which is a red powder, oil-soluble azo Dyes, soluble in benzene, ethanol and acetone.
  • oil-soluble azo Dyes soluble in benzene
  • ethanol ethanol
  • acetone a red powder
  • oil-soluble azo Dyes soluble in benzene
  • ethanol acetone
  • osteoblasts can be obtained by inducing osteogenic differentiation of adipose-derived stem cells under certain conditions.
  • a person skilled in the art can perform osteogenic induction of adipose stem cells using a general method.
  • a preferred chemical osteogenic induction formulation is: DMEM broth, sodium glycerophosphate, vitamin C and dexamethasone.
  • the process of osteogenic induction is to allow calcium ions to precipitate as calcium salts, or "calcium nodules.”
  • Alizarin red staining solution generally includes the following components: sodium bisulphonate, alizarin S, alizarin red S, alizarin carmine, sodium 1,2-dihydroxyindole-3-sulfonate, 1,2- Sodium dihydroxyindole-3-sulfonate.
  • Alizarin red is an orange-yellow or yellow-brown powder, soluble in water, slightly soluble in ethanol, insoluble in benzene and chloroform can form colored compounds with many metal ions, and can be combined with zirconium, hafnium, aluminum, titanium and barium and calcium. Color reaction.
  • Vitamin D is a sterol derivative, which is fat-soluble. Because of its anti-caries effect, it is also called anti-caries vitamin. VD can maintain the stability of serum calcium and phosphorus concentration.
  • the indicator when Ra ⁇ 5%, the indicator is effective, wherein
  • Ral is the concentration of vitamin D in the serum after the individual is returned
  • RaO is the concentration of vitamin D before the end of the return.
  • the inventors have found that an increase in the level of vitamin D helps to improve the health of the individual.
  • the amount of vitamin D in the blood increases significantly. The reason may be that adipose-derived stem cells can differentiate into bone cells, stimulate and induce secretion of parathyroid hormone, resulting in serum vitamin D concentration. rise.
  • Lipoprotein is a water-soluble protein complexed with lipids. They are usually classified into very low density lipoprotein, low density lipoprotein, high density lipoprotein, very high density lipoprotein and chylomicrons according to their density. Each lipoprotein contains the corresponding apolipoprotein.
  • High-density lipoprotein transports free cholesterol accumulated in peripheral tissues to lipoproteins in the blood circulation or to certain macromolecules and transports them to various tissue cells, mainly the liver. In fact, it is cholesterol reversal (RCR).
  • RCT cholesterol reversal
  • RCT promotes the clearance of cholesterol in tissue cells and maintains a relative balance of intracellular cholesterol, thereby limiting the development of atherosclerosis and exerting an anti-atherosclerotic effect.
  • LCAT converts HDL to HDL3 and HDL2 by transesterification, reduces the concentration of free cholesterol in plasma HDL, and constitutes a concentration gradient of cholesterol from the cell membrane to plasma lipoprotein, which reduces the deposition of tissue cholesterol.
  • LDL Low-density lipoprotein
  • Rbl is the high-density lipoprotein concentration in the serum after individual reinfusion
  • RbO is the high-density lipoprotein concentration before the end of the reinfusion
  • RcO is the low-density lipoprotein concentration before the end of the reinfusion
  • Rcl is the low-density lipoprotein concentration in the serum after the individual is reinfused.
  • the inventors have found that autologous return of adipose-derived stem cells helps to increase the concentration of high-density lipoprotein in serum and lower the concentration of low-density lipoprotein, thereby improving the health of the individual.
  • Thyrotropin thyroid stimulating hormone
  • Thyroid stimulating hormone is a hormone secreted by the pituitary gland to promote the growth and function of the thyroid gland.
  • Human TSH is a glycoprotein with 211 amino acids, and sugar accounts for about 15% of the entire molecule. The entire molecule consists of two peptide chains, an alpha chain and a beta chain.
  • TSH promotes the function of the thyroid gland in an all-round way. It is early to promote the release of thyroid hormones. Later, it promotes the synthesis of ⁇ 4 and ⁇ 3, including strengthening iodine pump activity, enhancing peroxidase activity, promoting thyroglobulin synthesis and cheese. Iodine iodization and other links. TSH promotes the metabolism of thyroid glandular epithelial cells and the synthesis of intracellular nucleic acids and proteins, causing the cells to proliferate in a high column, thereby increasing the gland.
  • the indicator when Rd ⁇ 5%, the indicator is effective, wherein
  • Rdl is the concentration of thyroid stimulating hormone in the serum after the individual is returned
  • RdO is the concentration of thyroid hormone before the end of the reinfusion.
  • TSH thyroid stimulating hormone
  • Testosterone is a steroid hormone secreted by the male testis or female ovaries. It is the main androgen in the human body, including the enhancement of sexual desire, strength, immune function and so on. As a prohormone, testosterone can also be converted to 17 ⁇ -estradiol by the action of aromatase.
  • the indicator when the individual is a male, and Re ⁇ 5%, the indicator is effective, wherein
  • Rel is the testosterone concentration in the serum after the individual is reinfused
  • ReO is the testosterone concentration before the end of the return.
  • autologous adipose-derived stem cells can contribute to an increase in testosterone concentration in an individual, possibly due to the differentiation of adipose-derived stem cells into bone cells, stimulating the differentiation of osteoclasts and osteoblasts, and inducing the formation of a link between bone and testosterone, resulting in The testosterone concentration in the serum increased.
  • Estradiol Estradiol is a form of estrogen.
  • Female estradiol is a natural estrogen secreted mainly by ovarian mature follicles, which promotes and regulates the normal development of female sexual organs and accessory sexual characteristics. Its main effects are: 1 promote endometrial hyperplasia; 2 enhance uterine smooth muscle contraction; 3 promote breast duct development and proliferation; 4 anti-androgenic effects; 5 lower blood cholesterol, increase calcium deposition in the bone.
  • the indicator when the individual is a female, and Rf ⁇ 5%, the indicator is effective, wherein
  • Rfl is the concentration of estradiol in the serum after the individual is returned
  • RfO is the concentration of estradiol before the end of the reinfusion.
  • the present inventors have found that autologous adipose stem cells can contribute to an increase in the concentration of estradiol in an individual to achieve an anti-aging effect. With age aging, estradiol shows a downward trend, while LH as a negative feedback of estradiol is increased. If estradiol is elevated, LH can be lowered to achieve anti-aging effects.
  • the main advantages of the present invention include:
  • the outer wall of the container containing the adipose tissue was wiped with 75% alcohol, and the sterile needle was taken from the body to remove the adipose tissue, and moved to the receiving container within 1 h.
  • the digested tissue was dispensed into a 50 ml centrifuge tube using a sterile 40-mesh filter, and centrifuged at 400 g for 10 minutes at room temperature to obtain a precipitate which was SVF.
  • the flat culture flask was placed in a carbon dioxide constant temperature and humidity incubator for cultivation at 37 ⁇ 0.5 ° C, and the carbon dioxide volume fraction was 5 ⁇ 0.2%. At the 24th hour of the primary culture, the whole amount of liquid was changed. After that, the liquid was changed every 3 days, and the carbon dioxide constant temperature and humidity incubator was placed for cultivation.
  • the washing solution is added to a centrifuge tube to a volume of 50 ml, and the pipette is suspended and suspended, ⁇ ⁇ Filter through a sterile filter and collect the filtrate into a 50 ml centrifuge tube, centrifuge at 1000 rpm for 10 min.
  • the density of the passaged cells is 5000-6000/cm 2 , ie (3.75-4.5 ) x l0 5 cells/T75, passaged according to 4.5 ⁇ 10 5 cells/ ⁇ 75, and cultured in a constant temperature and humidity incubator. Culture conditions: 37 ⁇ 0.5 ° C, carbon dioxide volume fraction of 5 ⁇ 0.2%, cultured to cell fusion of 85% -90%.
  • the cell yield isolated by the above method was: 5 x l 0 5 - lx 10 6 / ml fat.
  • the fold of P1 generation cells can be 1-2 times, and on the 14th day of culture, the fold of P2 generation cells can reach 4-6 times, and the 21st day of culture, the fold of P3 generation cells is expanded. Can reach 10 times.
  • Example 3
  • SVF and cultured adipose stem cells were collected into a centrifuge tube, and the cell suspension was adjusted to a density of lxl O 5 mL" 1 , 800 rpm (120 g), centrifuged for 5 min, the supernatant was discarded, and cold D-Hanks at 4 °C was used. Rinse the cells by rinsing, centrifuge the cell suspension again at 800 rpm for 5 min, then discard the supernatant. Then resuspend the cells to 1 mL with D-Hanks, add 5 ⁇ l of antibody, protect from light, and place on ice for 30 min.
  • adipose-derived stem cells There are many mixed cells in freshly isolated SVF (see Figure 1), which contains 10.5% CD45 (a typical hematopoietic stem cell surface antigen). , 77.8% (a typical antigen known to be located on the surface of white blood cells).
  • the cultured adipose stem cells are of very high purity and are essentially adipose-derived mesenchymal stem cells, such as 99.1% with CD29 surface antigen (recognized adipose-derived stem cell-specific antigen) and 98.5% with CD73 (recognized fat). Stem cell-specific antigens, while cells with CD14, CD4, CD34 antigens are rare.
  • the cultured stem cells were seeded in a six-well plate at a density of 1.5 X 10 5 per well to carry out an adipogenic induction experiment. Specifically, the final concentration is ⁇ ⁇ /L dexamethasone, 10 ⁇ /L insulin, 200 ⁇ /L indomethacin and 0.5 mmol/L.
  • Each group of samples was randomly selected from 5-10 fields for photographing to examine the effect of co-culture on the adipogenic differentiation.
  • the fat is bright red
  • the nucleus is blue
  • the interstitial is colorless.
  • Figure 3 shows the ability of isolated and cultured adipose stem cells to differentiate into adipocytes.
  • Figure 3A shows that adipose stem cells are capable of producing lipids under the action of an adipogenic inducer.
  • Figure 3B is a negative control of the adipogenic experiment, showing that in the absence of an adipogenic inducer, the adipose-derived stem cells are not self-generating into lipids (a large number of dense lipid droplets).
  • the cells were inoculated at a density of lxl0 5 ml, and the medium was cultured to change the induction medium: DMEM / 10% FBS, 0. ⁇ / L dexamethasone, 50 ⁇ / L vitamins (3, lOmmol / ⁇ -glycerol phosphate, 100 U / ml penicillin, 100 U / ml streptomycin; medium was changed every 3 days, induced culture for 2 weeks.
  • the cells were washed twice with PBS, fixed with 4% formaldehyde, stained with 1% alizarin red for 10 min, rinsed, dried, and mounted.
  • Figure 4 shows the ability of isolated and cultured adipose stem cells to differentiate into bone.
  • Figure 4A shows that adipose-derived stem cells are stained with alizarin red under the action of an osteogenic inducer, and a large amount of red calcified matrix deposition is observed in the cytoplasm.
  • Figure 4B shows a negative control of the osteogenic experiment in which adipose stem cells are not capable of spontaneous osteogenesis without the effect of an osteogenic inducer.
  • the cultured and identified adipose stem cell cells were injected into 30 ml of physiological saline to prepare a cell suspension for use in returning.
  • the first reinfusion was performed, and the total amount of stem cell reinfusion was 2 ⁇ 10 7 ; the adipose stem cells were cultured until the 30th day, and the second reinfusion was performed. The total amount of stem cell reinfusion was 2 ⁇ 10 7 ; day 90 for the third transfusion, total reinfusion of stem cells 2xl0 7 th. 4.
  • the serological examination was performed in the third month using conventional methods or commercially available test kits.
  • TSH thyroid stimulating hormone
  • Example 6 was repeated except that the test subjects were 10 females and 8 males, and serological tests were performed at 2.5 months and 4 months after the end of the reinfusion, including vitamin D, high density lipoprotein, Low density lipoprotein, thyroid stimulating hormone, estradiol (female), testosterone (male).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种自体脂肪干细胞抗衰老效果的评价体系,包括:对回输了脂肪干细胞的个体,在回输结束一段时间后进行血清学检测,其中血清学检测包括选自下组的一个或者多个指标:维生素D、高密度脂蛋白、低密度脂蛋白、促甲状腺激素、睾酮、雌二醇。该体系能够客观评价脂肪干细胞的抗衰老效果。

Description

一种自体脂肪干细胞抗衰老效果的评价体系 技术领域
本发明涉及生物技术及再生医学领域。 具体地, 本发明涉及一种自体脂肪干 细胞抗衰老效果的评价体系, 用本发明的体系能够准确、客观、及时地对脂肪干细 胞的抗衰老的效果进行评价。 背景技术
人类从胚胎发育、生命诞生到发育成熟、衰老直至死亡的整个生命过程中, 不可避免地会发生组织、 器官的损伤和功能衰退。 在正常生理过程中, 人体每 天都有大量细胞死亡, 同时伴有大量细胞的新生, 以维持各种组织和器官的完 整性, 保证功能处于正常状态。 如果细胞的死亡与新生失去平衡, 死亡细胞增 多或新生细胞减少, 就会导致组织器官功能的减退、 疾病发生, 甚至死亡。
衰老是人体随着年龄增长、 环境影响而发生的组织、 器官、 细胞的功能退 行性变化, 表现为机体的功能活动能力进行性下降, 对环境的适应能力逐渐降 低, 体内代谢平衡失调, 进而导致面色苍老、 皮肤松弛、 皱纹增多、 易疲劳、 脑力和体力劳动能力下降、 性功能减退等一系列衰老症状。 由于衰老是全身系 统性组织、 器官功能退化, 因此, 抗衰老和整形的策略也应考虑从整体水平改 善功能。
再生医学的兴起激发了人们对各种干细胞、 组织工程支架和细胞生长因子 的研究热潮。 干细胞 (stem cells, SC)是一类具有自我复制能力的多潜能细胞, 在一定条件下, 它可以分化成多种功能性细胞。干细胞可以对多种组织、器官、 系统的老化退行性病变进行再生性修复, 使其结构和功能正常化、 年轻化, 从 整体上调控机体状态, 是一种全身性、 系统性、 根本性的保健。
脂肪组织通常被认为是贮存能量及内分泌器官, 是软组织填充和吸脂处理 的必要组织, 脂肪组织在人体内储量丰富, 获取简便。 脂肪组织含有多种祖细 胞, 可分化为多种谱系, 主要包含脂肪细胞、 脂肪干细胞 (adipose-derived stem cells, ADSCs)、 血管内皮细胞、 成纤维细胞、 巨噬细胞及细胞外基质。 脂肪干 细胞 (adipose-derived stem cells, ADSCs)是一种具有多向分化潜能的干细胞,
ADSCs在体外稳定增殖且衰亡率低, 在体内体外具有多向分化潜能, 在不同的 诱导因子作用下可以向脂肪细胞、 软骨细胞、 肌细胞、 成骨细胞、 神经细胞、 神经胶质细胞及胰岛细胞分化, 而且可以分泌多种促血管生成因子和抗凋亡因 子。 脂肪干细胞来源广泛、 取材容易、 对机体损伤小, 体内储备量大、 少量组 织即可获取大量干细胞, 且适宜自体移植和大规模培养, 因此脂肪干细胞逐渐 成为近年来的研究热点之一, 同时也为一系列疾病的治疗提供了新的思路。
研究证明, 脂肪干细胞对新陈代谢和抗衰老有重要的调节功能, 脂肪干细 胞保健和治疗能提高机体对各种脂蛋白的代谢功能, 具有例如降低血中总胆固 醇浓度, 提高机体糖代谢功能, 降低血糖水平, 降低体重等功能。
因此尽管用于抗衰老的脂肪干细胞发展很快, 但是由于生物体的内外环境 的作用, 阻碍了自体脂肪干细胞抗衰老的评价体系的建立, 因此本领域需要开 发和建立一种快速、 准确、 经济的脂肪干细胞抗衰老的评价方法和体系。 发明内容
本发明的目的就是提供一种简便和 /或高效的一种自体脂肪干细胞抗衰老 效果的评价体系。
本发明提供了一种脂肪干细胞抗衰老的评价方法, 对回输了脂肪干细胞的 个体,在回输结束一段时间后进行血清学检测,所述的血清学检测包括检测选自下 组的一个或多个指标:
维生素 D、 高密度脂蛋白、 低密度脂蛋白、 促甲状腺激素、 睾酮、 雌二醇。
(a) 当 Ra≥5%时, 则该指标有效, 其中,
a = ( a 1 - aO) ÷ aO 100%,
式中, Ral为个体回输后血清中的维生素 D浓度, RaO为回输结束前的维生素 D 浓度;
(b) 当 Rb≥5%时, 则该指标有效, 其中,
b = ( bl- bO) ÷ bO 100%,
式中, Rbl为个体回输后血清中的高密度脂蛋白浓度, RbO为回输结束前的高 密度脂蛋白浓度; (c) 当 Rc≥5%时, 则该指标有效, 其中,
c = ( cO- cl) ÷ cO 100%,
式中, RcO为回输结束前的低密度脂蛋白浓度, Rcl为个体回输后血清中的低 密度脂蛋白浓度;
(d) 当 Rd≥5%时, 则该指标有效, 其中,
d=( dO- dl) ÷ dO 100%,
式中, RdO为回输结束前的促甲状腺激素的浓度, Rdl为个体回输后血清中促 甲状腺激素的浓度;
(e) 当个体是男性时, 且当 Re≥5%时, 则该指标有效, 其中,
e = ( el- eO) ÷ eO 100%,
式中, Rel为个体回输后血清中的睾酮的浓度, ReO为回输结束前的睾酮的浓 度;
(e) 当个体是女性时, 且当 Rf≥5%时, 则该指标有效, 其中,
f=( fl- fO) ÷ fO x 100%,
式中, Rfl为个体回输后血清中的雌二醇的浓度, RfO为回输结束前的雌二醇 的浓度;
并且, 当所述指标中至少一个指标为有效时, 则表示所述脂肪干细胞在所述 个体中产生抗衰老效果。
在另一优选例中, 当所述指标中有 2、 3和 4个指标为有效时, 则所述脂肪干细 胞在所述个体中产生抗衰老效果。
在另一优选例中, 所述的回输结束前, 包括回输开始之前、 回输过程中以及 回输结束时。
在另一优选例中, 所述的一段时间为≥1个月。
在另一优选例中, 所述的一段时间为 2-6个月, 较佳地为 3个月。
在另一优选例中, 所述回输的脂肪干细胞为培养 0-90天的脂肪干细胞。 在另一优选例中, 所述回输的脂肪干细胞为培养 30天的脂肪干细胞。
在另一优选例中, 所述脂肪干细胞是自体脂肪干细胞。
在另一优选例中, 当 Ra≥10%时, 提示回输的脂肪干细胞在所述个体中产生抗 衰老效果。 在另一优选例中, 当 Ra≥20%时, 提示回输的脂肪干细胞在所述个体中产生抗 衰老效果。
在另一优选例中, 当 Rb≥10%时, 提示回输的脂肪干细胞在所述个体中产生抗 衰老效果。
在另一优选例中, 当 Rb≥20%时, 提示回输的脂肪干细胞在所述个体中产生抗 衰老效果。
在另一优选例中, 当 Rc≥10%时, 提示回输的脂肪干细胞在所述个体中产生抗 衰老效果。
在另一优选例中, 当 Rc≥20%时, 提示回输的脂肪干细胞在所述个体中产生抗 衰老效果。
在另一优选例中, 当 Rd≥10%时, 提示回输的脂肪干细胞在所述个体中产生抗 衰老效果。
在另一优选例中, 当 Rd≥20%时, 提示回输的脂肪干细胞在所述个体中产生抗 衰老效果。
在另一优选例中, 当 Re≥10%时, 提示回输的脂肪干细胞在所述男性个体中产 生抗衰老效果。
在另一优选例中, 当 Re≥20%时, 提示回输的脂肪干细胞在所述男性个体中产 生抗衰老效果。
在另一优选例中, 当 Rf≥10%时, 提示回输的脂肪干细胞在所述女性个体中产 生抗衰老效果。
在另一优选例中, 当 Rf≥20%时, 提示回输的脂肪干细胞在所述女性个体中产 生抗衰老效果。
在另一优选例中, 所述的回输的脂肪干细胞的具有以下一个或多个特征:
(i) 95%以上的细胞具有表面抗原 CD29;
(ii) 90%以上的细胞具有表面抗原 CD73 ;
(iii) 90%以上的细胞具有表面抗原 CD49d; 和
(iv) 90%以上的细胞具有表面抗原 CD90。
在另一优选例中, 99%以上的细胞具有表面抗原 CD29。
在另一优选例中, 95%以上的细胞具有表面抗原 CD73。 在另一优选例中, 95%以上的细胞具有表面抗原 CD49d
在另一优选例中, 95%以上的细胞具有表面抗原 CD90。
在另一优选例中, 所述脂肪干细胞还具有以下特征:
(v) 5%以下的细胞具有表面抗原 CD34; 和 /或
(vi)0.05%以下的细胞具有表面抗原 CD45。
在另一优选例中, 3%以下的细胞具有表面抗原 CD34
在另一优选例中, 0%的细胞具有表面抗原 CD45。 应理解,在本发明范围内中,本发明的上述各技术特征和在下文 (如实施例) 中具体描述的各技术特征之间都可以互相组合, 从而构成新的或优选的技术方 案。 限于篇幅, 在此不再一一累述。 附图说明
图 1显示了用流式细胞仪法对制备的 SVF进行表面抗原标记表达的分析结 果。
图 2显示了用流式细胞仪法对经培养的脂肪干细胞群进行表面抗原标记表 达的分析结果。
图 3显示了分离和培养的脂肪干细胞具有分化为脂肪的能力; 其中, 图 3A显示在成脂诱导剂作用下, 脂肪干细胞能够生成脂质, 胞浆中可见生 产大量的红色脂滴;
图 3B为成脂实验的阴性对照, 在没有成脂诱导剂的作用下, 脂肪干细胞不 能够自发生成脂质。
图 4显示了分离和培养的脂肪干细胞具有分化为骨的能力; 其中, 图 4A显示脂肪干细胞在成骨诱导剂作用下, 经茜素红染色, 可见细胞浆中 有红色的钙化基质沉积;
图 4B显示成骨实验的阴性对照, 在没有成骨诱导剂的作用下, 脂肪干细胞 不能够自发成骨。
图 5显示了回输脂肪干细胞的受试者, 其血液中维生素 D的浓度显著上升。 图 6显示了回输脂肪干细胞的受试者, 高密度脂蛋白 (HDL)的浓度显著上 升。
图 7显示了回输脂肪干细胞的受试者, 低密度脂蛋白 (LDL)的浓度均显著下 降。
图 8显示进行脂肪干细胞回输后的男性受试者, 其血清中睾酮的浓度显著 上升。
图 9显示进行脂肪干细胞回输后的女性受试者, 其血清中雌二醇的浓度显 著上升。
图 10显示了回输脂肪干细胞的受试者,其血清中促甲状腺激素的浓度均显 著下降。 具体实施方式
本发明人经过广泛而深入的研究, 意外地发现, 在可供检测的大量的血清 学指标中, 维生素 D、 高密度脂蛋白、 低密度脂蛋白、 促甲状腺激素、 睾酮(男 性) 、 雌二醇 (女性) 的含量变化可以作为评价自体脂肪干细胞抗衰老效果的 有效性指标, 当所述指标中至少一个指标为有效时, 则表示所述脂肪干细胞在所 述个体中产生抗衰老效果。 与此相反, 胆固醇, 血糖, 总脂蛋白等的浓度不能作为 评估脂肪干细胞抗衰老效果的有效性指标。用本发明的评价体系能够客观地对脂 肪干细胞的抗衰老的效果进行评价, 并且具有快速、 准确、 经济的优点。 在此基 础上完成了本发明。 术语
如本文所用, 术语"以上"和"以下"包括本数, 例如" 95%以上"指≥95%,"0.2% 以下"指≤0.2%。 脂肪
自体脂肪是整形和抗衰老治疗的优良来源,脂肪组织材料可以来源于腰部、 臀部、 腹部、 大腿、 上臂等部位。 本领域技术人员可采用通用的技术方法获得 自体脂肪组织, 包括 (但不限于) 抽吸、 手术分离等方法。 间质血管碎片 (SVF)
SVF是干细胞辅助脂肪移植中最重要的组分。 通过胶原酶消化, 从脂肪组 织中分离的多种细胞混合物形成的细胞团就叫做间质血管碎片。 间质血管碎片 中含有丰富的间充质细胞, 可分化为多种谱系的细胞, 是再生医学、 组织工程 等最理想的种子细胞,
本领域的技术人员能够使用通用的方法进行 SVF的纯化, 在一个优选的实 施例中, 分离 SVF可以包括以下步骤 (但不限于):
将吸脂后的脂肪用 PBS反复冲洗两次,然后在 37°C条件下用胶原酶消化 30min, 用含 10%胎牛血清的 DMEM终止消化, 1200g离心 lOmin后即获得高密 度的 SVF碎片, 其中主要包括间质细胞、 血管内皮细胞和壁细胞。 另外, SVF 中也包括一些血管来源的细胞, 如白细胞和红细胞等, 各种细胞之间具有协同 效应。 脂肪干细胞
如本文所用, 术语"脂肪干细胞"、 "本发明脂肪干细胞"、 或"本发明的干细 胞"可以互换使用, 都是指分离自脂肪组织的干细胞。 脂肪干细胞 (ADSCs)是从 脂肪组织中分离得到的一种具有多向分化潜能的干细胞。 ADSCs能够在体外稳 定增殖且衰亡率低, 它取材容易、 体内储备量大、 适宜大规模培养、 对机体损 伤小、 来源广泛、 适宜自体移植。
在本发明中, 脂肪组织或脂肪的原料没有特别限制, 可以是来源于动物或 人的任何部位的脂肪组织, 优选人的脂肪组织。较佳地, 脂肪组织可以是腰部、 臀部、 腹部、 大腿、 上臂等部位的组织。 干细胞抗原检测
脂肪干细胞群具有多种特异性抗原和受体, 主要有 D29、 CD73、 CD49d、
CD90、 CD14、 CD45、 CD34、 CD3、 CD13、 CD59、 CD105等。
CD34抗原是一种高度糖基化的 I型跨膜蛋白,它选择性的表达于人类造血 干细胞 (HSC),祖细胞 (PC)和血管内皮细胞 (EC)表面, 是脂肪干细胞的阴性指标, 带有 CD34的脂肪干细胞在总干细胞的比例优选为≤5%, 更佳地, ≤3%。 CD45存在于所有造血细胞的表面, 包括造血干细胞和破骨细胞, 是脂肪干 细胞的阴性指标, 带有 CD45的脂肪干细胞在总干细胞的比例优选为≤0.1%, 更 佳地, 为 0%。
CD29、 CD73、 CD90、 CD49d等主要存在于脂肪间充质干细胞表面。
带有 CD29的脂肪干细胞在总干细胞的比例优选为≥95%, 更佳地≥97%, 最 佳地≥99%。
带有 CD73的脂肪干细胞在总干细胞的比例优选为≥80%, 更佳地≥85%, 最 佳地≥88%。
带有 CD90的脂肪干细胞在总干细胞的比例优选为≥75%, 更佳地≥78%, 最 佳地≥80%。
带有 CD49d的脂肪干细胞在总干细胞的比例优选为≥90%, 更佳地≥95%, 最佳地≥99%。
本领域内技术人员可以使用通用的方法检测脂肪干细胞的纯度和分化程 度, 如流式细胞仪法。 检测时, 加入不同的与有针对性的特异抗体, 抗体可以 是完整的单克隆或多克隆抗体, 也可以是具有免疫活性的抗体片段, 如 Fab'或 (Fab)2片段; 抗体重链; 抗体轻链; 遗传工程改造的单链 Fv分子; 或嵌合抗体, 如具有鼠抗体结合特异性但仍保留来自人的抗体部分的抗体。 加入抗体与细胞 表面的抗原结合一定时间, 用流式细胞仪对细胞进行自动分析和分选。 成脂诱导及检测
由于脂肪干细胞具有多向分化能力, 在一定的条件下对脂肪干细胞进行分 化诱导, 能够得到特定功能的已分化的细胞。
本领域内技术人员可以使用通用的方法对脂肪干细胞进行成脂诱导。 一种 优选的诱导方法是向培养液中加入地塞米松。 含地塞米松的诱导剂主要有 3种, 1.地塞米松加 1-甲基 -3-异丁基黄嘌呤 (IBMX), 2.地塞米松加胰岛素, 3.地塞米 松加茚甲新 (indomethacin, 消炎痛)、 1-甲基 -3-异丁基黄嘌呤及胰岛素。 低浓度 的地塞米松是无血清或低血清培养间充质干细胞的必需成分之一, 能够促进间 充质干细胞的体外快速增殖; 较高浓度的地塞米松则可以诱导间充质干细胞向 脂肪细胞分化。 本领域内技术人员可以使用通用的方法和染料 (如 Oil Red, 苏丹红 5B和溶 剂红 27等)对脂肪干细胞诱导成脂进行检测。 一种优选的染料是 Oil Red(O), 即 油红 0。 油红 O的结构为 1- [ 2,5-二甲基 -4-(2,5-二甲基苯偶氮)苯偶氮] -2萘酚, 是一种红色粉末, 油溶性偶氮染料, 易溶于苯、 乙醇和丙酮。 成脂肪诱导的过 程中, 细胞在胞浆中不断有油滴的累积, 并不断的增加变大, 最后整个细胞的 胞浆中都是油滴。 油红 O作为生物染色剂, 易与油脂结合, 但与细胞本身的结 构着色力差。 在显微镜下可以清楚地进行成脂染色观察。 成骨诱导及检测
由于脂肪干细胞具有多向分化能力, 在一定的条件下对脂肪干细胞进行成 骨分化诱导, 能够得到成骨细胞。
本领域内技术人员可以使用通用的方法对脂肪干细胞进行成骨诱导。一种优选 的化学成骨诱导液配方为: DMEM培养液, 甘油磷酸钠, 维生素 C和地塞米松。 成骨诱导的过程是使钙离子能够以钙盐的方式沉淀下来, 即"钙结节"。
一种优选的鉴定钙结节的染料未"茜素红"。 茜素红染色液一般包括以下组分: 茜素磺酸钠, 茜素 S, 茜素红 S, 茜素胭脂红, 1,2-二羟基蒽醌 -3-磺酸钠, 1,2-二羟 基蒽醌 -3-磺酸钠盐。 茜素红为橙黄色或黄棕色粉末, 易溶于水, 微溶于乙醇, 不 溶于苯和氯仿能与许多金属离子生成带色化合物, 能与锆、 钍、 铝、 钛及铍和钙的 显色反应。茜素红染色的原理就是茜素红和钙发生显色反应,产生一种深红色的带 色化合物, 这样成骨诱导的细胞外面沉积的钙结节也就被染成了深红色。 维生素 D(Vitamin D, VD)
维生素 D(Vitamin D, VD)为固醇类衍生物, 脂溶性, 由于具抗佝偻病作用, 又称抗佝偻病维生素, VD能够维持血清钙磷浓度的稳定。
在本发明中, 当 Ra≥5%时, 则该指标有效, 其中,
a = ( a 1 - aO) ÷ a0 100%,
式中, Ral为个体回输后血清中的维生素 D浓度, RaO为回输结束前的维生素 D 浓度。
本发明人发现, 维生素 D水平的提高, 有助于提高个体的健康水平。 当个体 回输自体脂肪干细胞后, 其血液中的维生素 D的含量有大幅上升, 其原因可能是脂 肪干细胞可以分化为骨细胞, 剌激并诱导甲状旁腺素分泌的分泌, 导致血清中的 维生素 D浓度上升。 月旨蛋白 (Lipoprotein)
脂蛋白是一种与脂质复合的水溶性蛋白质。 通常根据其密度分为极低密度 脂蛋白、 低密度脂蛋白、 高密度脂蛋白、 极高密度脂蛋白和乳糜微粒。 每一种 脂蛋白中均含有相应的载脂蛋白。
高密度脂蛋白 (HDL)可将蓄积于末梢组织的游离胆固醇与血液循环中脂蛋 白或与某些大分子结合而运送到各组织细胞, 主要是肝脏。 实际上是胆固醇逆 转 (RCR), RCT促进组织细胞内胆固醇的清除, 维持细胞内胆固醇量的相对衡 定, 从而限制动脉粥样硬化的发生发展, 起到抗动脉粥样硬化作用。 LCAT通 过转酯化反应完成新生盘状 HDL向 HDL3、 HDL2的转化, 减少血浆 HDL中游离 胆固醇的浓度, 构成胆固醇从细胞膜流向血浆脂蛋白的浓度梯度, 降低组织胆 固醇的沉积。
低密度脂蛋白 (LDL)是富含胆固醇的脂蛋白, 主要作用是将胆固醇运送到 外周血液,是动脉粥样硬化的危险因素之一,被认为是致动脉粥样硬化的因子。
在本发明中,
当 Rb≥5%时, 则该指标有效, 其中,
b = ( b 1 - bO) ÷ bO 100%,
式中, Rbl为个体回输后血清中的高密度脂蛋白浓度, RbO为回输结束前的高 密度脂蛋白浓度。
当 Rc≥5%时, 则该指标有效, 其中,
c = ( c0- cl) ÷ cO 100%,
式中, RcO为回输结束前的低密度脂蛋白浓度, Rcl为个体回输后血清中的低 密度脂蛋白浓度。
本发明人发现, 自体回输脂肪干细胞, 有助于提高血清中高密度脂蛋白的 浓度, 降低低密度脂蛋白浓度, 从而提高个体的健康水平。 促甲状腺激素 ( Thyrotropin, thyroid stimulating hormone)
促甲状腺激素是腺垂体分泌的促进甲状腺的生长和机能的激素。 人类的 TSH为一种糖蛋白, 含 211个氨基酸, 糖类约占整个分子的 15 %。 整个分子由两 条肽链一 α链和 β链组成。 TSH全面促进甲状腺的机能, 稍早出现的是促进甲状 腺激素的释放, 稍晚出的为促进 Τ4、 Τ3的合成, 包括加强碘泵活性, 增强过氧 化物酶活性, 促进甲状腺球蛋白合成及酪氨酸碘化等各个环节。 TSH促进甲状 腺上皮细胞的代谢及胞内核酸和蛋白质合成, 使细胞呈高柱状增生, 从而使腺 体增大。
在本发明中, 当 Rd≥5%时, 则该指标有效, 其中,
d=( dl - dO) ÷ dO 100%,
式中, Rdl为个体回输后血清中促甲状腺激素的浓度, RdO为回输结束前促甲 状腺激素的浓度。
TSH和甲状腺的产生和功能之间是一个反比关系, 高的促甲状腺激素, 标 志着低甲状腺的生成和功能。本发明人发现, 自体脂肪干细胞回输治疗后, TSH 的水平在 1个月和 3个月期间内显著下降, 表明甲状腺激素的产生和功能有显著 改善, 自体脂肪干细胞的回输缓解了年龄相关疾病。 睾酮 (Testosterone)
睾酮是由雄性睾丸或雌性卵巢分泌的一种类固醇激素。 是人体内主要的雄 激素, 包括增强性欲、 力量、 免疫功能等功效。 睾酮作为一种激素原, 还能够 在芳香化酶的作用下可转变为 17β-雌二醇。
在本发明中, 当个体为男性, 且 Re≥5%时, 则该指标有效, 其中,
e = ( el- e0) ÷ eO 100%,
式中, Rel为个体回输后血清中的睾酮浓度, ReO为回输结束前的睾酮浓度。 本发明人发现, 自体脂肪干细胞可以有助于提高个体的睾酮浓度, 原因可 能是脂肪干细胞分化为骨细胞, 剌激破骨细胞和成骨细胞的分化, 诱导骨骼与 睾酮间关联的形成, 导致血清中的睾酮浓度上升。 雌二醇 (Estradiol) 雌二醇是一种 体雌激素。 女性雌二醇是主要由卵巢成熟滤泡分泌的一种天 然雌激素, 能促进和调节女性性器官及副性征的正常发育。其主要作用为: ①促使 子宫内膜增生; ②增强子宫平滑肌的收缩; ③促使乳腺导管发育增生;; ④抗雄激 素作用; ⑤降低血中胆固醇, 增加钙在骨中的沉着。
在本发明中, 当个体为女性时, 且 Rf≥5%时, 则该指标有效, 其中,
f=( fl- fO) ÷ fO X 100%,
式中, Rfl为个体回输后血清中雌二醇浓度, RfO为回输结束前雌二醇浓度。 本发明人发现, 自体脂肪干细胞可以有助于提高个体的雌二醇浓度, 达到 抗衰老的效果。随着年龄的衰老, 雌二醇呈下降趋势,而 LH作为雌二醇的负反馈 是上升的,如果雌二醇升高,可使 LH下降,达到抗衰老目的. 本发明的主要优点包括:
(1)安全: 抽取血清对少量指标进行检测, 无副作用;
(2)便捷: 在一个小时内就可以作出脂肪干细胞抗衰老的效果的评价; (3)准确: 维生素 D、 高密度脂蛋白、 低密度脂蛋白、 促甲状腺激素、 雌二醇、 睾酮等可以作为评价脂肪干细胞抗衰老的重要指标, 血清检测学方法成熟可靠。 下面结合具体实施例, 进一步阐述本发明。 应理解, 这些实施例仅用于说 明本发明而不用于限制本发明的范围。 下列实施例中未注明具体条件的实验方 法,通常按照常规条件,例如 Sambrook等人, 分子克隆: 实验室手册 (New York: Cold Spring Harbor Laboratory Press, 1989)中所述的条件, 或按照制造厂商所建 议的条件。 除非另外说明, 否则百分比和份数是重量百分比和重量份数。 实施例 1
基质血管组分 (SVF)的获得
1. 获得脂肪组织
用 75%的酒精擦拭装脂肪组织的容器外壁,无菌针管从人体吸取脂肪组织, lh内将其移至接收容器内。
2. 分装脂肪组织 每一个培养瓶分装脂肪组织为 50ml, 用 10ml移液管在脂肪采集瓶吸取下层 红色液体, 弃掉, 剩余的上层脂肪混匀后进行分装。
3. 洗涤脂肪组织除去血细胞
向培养瓶中加入 100ml氯化钠注射液, 拧紧盖子, 剧烈晃动 3分钟以充分洗 涤脂肪组织, 接着静止 3-5分钟, 使不同相分离, 吸去下层水相; 重复以上操作 三次, 直到下层液较为清澈。
4. 胶原酶 I消化
加入等量新配制的预热 (提前半小时于 37°C的气浴摇床预热)的胶原酶 I溶 液, 封口膜封口, 剧烈晃动培养瓶 5-10秒, 置于振动气浴锅中, 37°C, 70rpm, 消化 60分钟, 每隔 15分钟剧烈晃动培养瓶 5-10秒, 直到看起来较为平滑。
5. 分离基质血管组分 (SVF)
将消化后的组织用无菌 40目滤网分装到 50ml的离心管中, 室温 400g离心 10 分钟, 得到的沉淀即为 SVF。
6. 净化沉淀
离心后, SVF沉积于离心管底部, 用移液管自上而下小心除去上层油脂和 下层的胶原酶溶液。 需要在 SVF沉淀上方留下少量的溶液, 以免扰动沉淀细胞。 用适量的生理盐水重悬细胞, 吹散, 在室温下 400g离心 10分钟。 10ml培养基悬 浮细胞, 然后将细胞汇总到 50ml离心管中, 过 100目筛, 再次室温 300g离心 10 分钟, 得到经净化的 SVF沉淀。 实施例 2
脂肪干细胞种植和培养
1. 细胞种植
离心后的 SVF加 20ml培养基, 并充分混匀, 根据培养瓶的面积, 用基于组 织块法进行细胞种植,按照每平方厘米接种 0.16ml抽脂得到的脂肪量进行接种, 每 100ml脂肪组织, 最终可以接种 8个 T75培养瓶。
2. 原代细胞培养
将平置的培养瓶放置于二氧化碳恒温恒湿培养箱进行培养, 培养条件为 37±0.5 °C, 二氧化碳体积分数为 5±0.2%。 原代培养第 24小时, 进行全量换液。 此后每隔 3天全量换液, 放置二氧化碳恒温恒湿培养箱进行培养。
3. 原代细胞收获
7天左右, 原代培养的细胞克隆团的面积百分比到达 70%-80%, 消化收获。 在培养瓶中加入消化酶 (消化酶为 0.125% Trypsin-0.01% EDTA溶液, 使用前室 温放置 15min, 每 75cm2加入 2ml消化酶溶液), 消化时间为 1.5min, 加入培养基 2ml, 反复吹打瓶底至细胞大部分脱落,移入 50ml离心管中, 原培养瓶中加入 5ml 氯化钠注射液, 并冲洗瓶壁, 将洗液加入离心管中定容至 50ml, 移液管吹打悬 浮, Ι ΟΟμιη无菌滤网过滤, 将过滤液收集到 50ml离心管中, 1000rpm, l Omin离 心。
4. 原代细胞传代
观察单个离心管内余下细胞沉淀量, 适当合并数个离心管中细胞沉淀至 1 个离心管中, 加入适量培养基, 轻轻吹打重悬浮细胞, 定容至 30ml, 吹打混匀, 取样计数。 计数后 l OOOrpm, l Omin二次离心。 去除上清液, 在离心管中加入适 量培养基, 轻轻吹打重悬浮细胞, 定容后接种至新的培养容器中, 传代的细胞 密度为 5000-6000个 /cm2, 即(3.75-4.5)x l05个细胞 /T75, 按照 4.5χ 105个细胞 /Τ75 进行传代, 并置于二氧化碳恒温恒湿培养箱开始培养。 培养条件: 37±0.5 °C, 二氧化碳体积分数为 5±0.2%, 培养至细胞融合达 85%-90%。
经上述方法分离的细胞得率为: 5x l 05-l x l06个 /ml脂肪。 培养第 7天, P1代细 胞扩增的倍数可以达到 1 -2倍, 培养第 14天, P2代细胞扩增的倍数可以达到 4-6 倍, 培养第 21天, P3代细胞扩增的倍数可以达到 10 倍。 实施例 3
抗原标记检测
分别将 SVF和培养后的脂肪干细胞收集到离心管中, 细胞悬液调整密度为 l x l O5 mL"1 , 800rpm (120g) , 离心 5 min, 弃上清, 用 4 °C的冷 D-Hanks 冲洗重 悬细胞,再次将细胞悬液以 800 rpm,离心 5 min,之后弃去上清。然后用 D-Hanks 将细胞重悬至 l mL, 加入抗体 5μ1, 避光, 冰上放置 30 min。 用 D-Hanks 冲洗, 离心, 弃上清, 重复该冲洗过程 2次, 确保将未结合抗体除净最后, 加入约 200μ1 的 D-Hanks 制成悬液, 用流式细胞仪检测。 加入的抗体分别为: 人抗 CD29、 CD73、 CD49d、 CD90、 CD14、 CD34、 CD45、 CD34、 Actin和 HLA-DR。 抗原检测结果见表 1。 表 1
Figure imgf000016_0001
表明:通过流式细胞仪对脂肪干细胞进行细胞表面抗原标记表达的分析,新 鲜分离的 SVF中混合细胞较多 (见图 1),其中含有 10.5%的 CD45(—种典型的造血 干细胞表面抗原), 77.8%的 (一种已知位于白细胞表面的典型抗原)。 而经过培 养的脂肪干细胞 (见图 2)纯度非常高,基本上都是脂肪间充质干细胞, 例如 99.1% 具有 CD29表面抗原 (公认的脂肪干细胞特异性抗原), 98.5%具有 CD73(公认的脂 肪干细胞特异性抗原),而具有 CD14, CD4, CD34抗原的细胞极少。 实施例 4
脂肪干细胞的成脂诱导
1.将培养的干细胞以 1.5 X 105每孔的密度接种在六孔板中, 进行成脂诱导实 验。 具体方法是: 向基础培养基 (DMEM+10%胎牛血清)中加入终浓度分别为 Ι μιηοΐ/L地塞米松、 10 μιηοΙ/L 胰岛素、 200 μιηοΙ/L 吲哚美辛和 0.5mmol/L的异 丁基甲基黄嘌呤, 配制成脂诱导培养基, 以正常培养基培养的样本为成脂分化 实验阴性对照组。 每周换 2次液, 直到进行成脂染色观察为止, 以上组均做平 行实验 (n=3)。
2.油红 O染色
先小心轻缓倒去培养液, 用 D-hanks轻缓漂洗, 加 10%中性甲醛固定细胞膜 30min。 加入 0.5%油红 O(六孔板力口 1.5ml), 染色 lh左右。
3.脱色, 75%酒精 /60%异丙醇漂洗, 除去多余的染料。 4.复染, 淡苏木染色 lmin, PBS漂洗。
5.甘油明胶封片, 显微镜观察
每组样本随机选取 5-10个视野进行拍照观察以考察共培养方法的成脂诱导 分化效果。 脂肪呈鲜红色, 细胞核呈蓝色, 间质无色。
6.结果
图 3显示了分离和培养的脂肪干细胞具有分化为脂肪细胞的能力。
图 3A显示在成脂诱导剂作用下, 脂肪干细胞能够生成脂质。
图 3B为成脂实验的阴性对照, 表明在没有成脂诱导剂的作用下, 脂肪干细 胞不能够自发生成脂质 (大量密集在一起的小脂滴)。 实施例 5
脂肪的干细胞成骨诱导
1.成骨细胞分化
胰酶消化培养的脂肪细胞后, 以 lxl05ml密度接种传代, 基础培养基培养 Id 后更换诱导培养基: DMEM / 10%FBS, 0. Ιμιηο / L地塞米松, 50μιηο / L维生 素(3, lOmmol / β-甘油磷酸钠, 100U / ml青霉素, 100U / ml链霉素; 每 3d更换 培养基, 诱导培养 2周。
2.茜素红染色
细胞以 PBS洗涤 2次, 4%甲醛固定, 1%茜素红染色 lOmin,冲洗, 干燥, 封片。
3.观察
每组样本随机选取 5-10个视野进行拍照观察以考察成骨诱导分化效果。 利 用沉积的钙于茜素红可以发生显色反应,诱导成骨的细胞经茜素红染色,可见细 胞浆中有大量红色的钙化基质沉积。
4.结果
图 4显示了分离和培养的脂肪干细胞具有分化为骨的能力.
图 4A显示脂肪干细胞在成骨诱导剂作用下, 经茜素红染色,可见细胞浆中 有大量红色的钙化基质沉积。
图 4B显示成骨实验的阴性对照, 在没有成骨诱导剂的作用下, 脂肪干细胞 不能够自发成骨。 实施例 6
脂肪干细胞抗衰老评价
1.将经培养和鉴定的脂肪干细胞细胞注入 30ml生理盐水,制备成细胞悬液, 以备回输使用。
2.三次静脉回输:
脂肪干细胞分离当天,进行第一次回输,干细胞回输总量为 2xl07个; 脂肪干细胞培养至第 30天, 进行第二次回输, 干细胞回输总量为 2xl07个; 脂肪干细胞培养至第 90天, 进行第三次回输, 干细胞回输总量为 2xl07个。 4. 回输前以及回输后的第一个月,第三个月分别用常规方法或市售检测试 剂盒进行血清学检测。
其中部分数据结果见表 2。
Figure imgf000019_0001
从表 2的结果可以看出,脂肪干细胞混合物回输三个月后, 受试者 (男性和 女性) 的血液中维生素 D的含量都有显著上升 (图 5 ) , 上升幅度分别为
12%- 157%。
高密度脂蛋白则有所提高, 上升幅度为 15%左右 (图 6), 而低密度脂蛋白的 含量减少幅度为 8%-16% (图 7)。
回输干细胞, 男性中, 睾酮的上升幅度为 7%左右 (图 8 ) 。
女性的雌二醇有明显的上升趋势 (图 9), 上升幅度为 9%-78%。
TSH和甲状腺的产生和功能之间是一个反比关系。 高的促甲状腺激素, 标 志着低甲状腺的生成和功能。 治疗后, TSH的水平在 1个月和 3个月期间内显著 下降, 下降幅度分别为为 70%,60%,10%, 表明甲状腺激素的产生和功能有显著 改善, 自体脂肪干细胞的回输缓解了年龄相关疾病。 图 10中只是两例老年女性 下降不明显,可以忽略,其他都是显著下降,不分男女。
因此, 脂肪干细胞回输三个月后, 受试者的内分泌得到调整, 并且在整体 水平上加强组织和器官功能。 实施例 7
重复实施例 6, 不同点在于, 测试对象为 10个女性和 8男性, 并且在回输结 束后的 2.5个月和 4个月进行血清学检测,其中检测指标包括维生素 D、高密度脂 蛋白、 低密度脂蛋白、 促甲状腺激素、 雌二醇 (女性) 、 睾酮 (男性) 。
结果表明, 90%以上受试个体, 有 1个指标是有效的; 80%以上受试个体, 有 2个指标是有效的; 50%以上受试个体, 有 3个指标是有效的; 30%以上受试 个体, 有 4个指标是有效的, 25%以上受试个体, 有 5个指标是有效的。 在本发明提及的所有文献都在本申请中引用作为参考, 就如同每一篇文献 被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后, 本领域技术人员可以对本发明作各种改动或修改, 这些等价形式同样落于本申 请所附权利要求书所限定的范围。

Claims

权 利 要 求
1.一种脂肪干细胞抗衰老的评价体系, 其特征在于, 对回输了脂肪干细胞的 个体,在回输结束一段时间后进行血清学检测,所述的血清学检测包括检测选自下 组的一个或多个指标:
维生素 D、 高密度脂蛋白、 低密度脂蛋白、 促甲状腺激素、 睾酮、 雌二醇;
(a) 当 Ra≥5%时, 则该指标有效, 其中,
a = ( a 1 - aO) ÷ aO 100%,
式中, Ral为个体回输后血清中的维生素 D浓度, RaO为回输结束前的维生素 D 浓度;
(b) 当 Rb≥5%时, 则该指标有效, 其中,
b = ( bl- bO) ÷ bO 100%,
式中, Rbl为个体回输后血清中的高密度脂蛋白浓度, RbO为回输结束前的高 密度脂蛋白浓度;
(c) 当 Rc≥5%时, 则该指标有效, 其中,
c = ( c0- cl) ÷ cO 100%,
式中, RcO为回输结束前的低密度脂蛋白浓度, Rcl为个体回输后血清中的低 密度脂蛋白浓度;
(d) 当当 Rd≥5%时, 则该指标有效, 其中,
d=( dl - dO) ÷ dO 100%,
式中, Rdl为个体回输后血清中促甲状腺激素的浓度, RdO为回输结束前促甲 状腺激素的浓度;
(e) 当个体是男性时, 且当 Re≥5%时, 则该指标有效, 其中,
e = ( el- eO) ÷ eO 100%,
式中, Rel为个体回输后血清中的睾酮的浓度, ReO为回输结束前的睾酮的浓 度;
(f) 当个体是女性时, 且当 Rf≥5%时, 则该指标有效, 其中,
f=( fl- fO) ÷ fO x 100%,
式中, Rfl为个体回输后血清中的雌二醇的浓度, RfO为回输结束前的雌二醇 的浓度;
并且, 当所述指标中至少一个指标为有效时, 则表示所述脂肪干细胞在所述 个体中产生抗衰老效果。
2. 如权利要求 1所述的评价体系, 其特征在于, 所述的回输结束前, 包括回 输开始之前、 回输过程中以及回输结束时。
3. 如权利要求 1所述的评价体系, 其特征在于, 所述的一段时间为≥1个月。
4. 如权利要求 1所述的评价体系, 其特征在于, 所述的回输的脂肪干细胞 为培养 0-90天的脂肪干细胞。
5. 如权利要求 1所述的评价体系, 其特征在于, 当 Ra≥10%时, 提示回输的 脂肪干细胞在所述个体中产生抗衰老效果。
6. 如权利要求 1所述的评价体系, 其特征在于, 当 Rb≥10%时, 提示回输的 脂肪干细胞在所述个体中产生抗衰老效果。
7. 如权利要求 1所述的评价体系, 其特征在于, 当 Rc≥10%时, 提示回输的 脂肪干细胞在所述个体中产生抗衰老效果。
8. 如权利要求 1所述的评价体系, 其特征在于, 当 Rd≥10%时, 提示回输的 脂肪干细胞在所述个体中产生抗衰老效果。
9.如权利要求 1所述的评价体系, 其特征在于, 当 Re≥10%时, 提示回输的脂 肪干细胞在所述男性个体中产生抗衰老效果。
10. 如权利要求 1所述的评价体系, 其特征在于, 当 Rf≥10%时, 提示回输 的脂肪干细胞在所述女性个体中产生抗衰老效果。
PCT/CN2012/070995 2011-09-27 2012-02-09 一种自体脂肪干细胞抗衰老效果的评价体系 WO2013044607A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110301615.4A CN102486475B (zh) 2011-09-27 2011-09-27 一种自体脂肪干细胞抗衰老效果的评价方法
CN201110301615.4 2011-09-27

Publications (1)

Publication Number Publication Date
WO2013044607A1 true WO2013044607A1 (zh) 2013-04-04

Family

ID=46151993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/070995 WO2013044607A1 (zh) 2011-09-27 2012-02-09 一种自体脂肪干细胞抗衰老效果的评价体系

Country Status (2)

Country Link
CN (1) CN102486475B (zh)
WO (1) WO2013044607A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102486475B (zh) * 2011-09-27 2015-12-02 西比曼生物科技(香港)有限公司 一种自体脂肪干细胞抗衰老效果的评价方法
CN104931681A (zh) * 2015-07-14 2015-09-23 广州赛莱拉干细胞科技股份有限公司 一种检测免疫细胞对血清生化指标或亚健康改善效果的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157071A1 (en) * 2001-05-31 2003-08-21 Wolfe M. Michael Treatment or replacement therapy using transgenic stem cells delivered to the gut
WO2007006862A2 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method and kit for detecting a risk of coronary heart disease
CN102002475A (zh) * 2010-03-10 2011-04-06 和泽生物科技有限公司 人脂肪成体干细胞的获取方法及该干细胞库的构建方法
CN102486475A (zh) * 2011-09-27 2012-06-06 臻景生物技术(上海)有限公司 一种自体脂肪干细胞抗衰老效果的评价体系

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502124A (ja) * 2005-07-15 2009-01-29 プライムジェン バイオテック エルエルシー 生殖系列幹細胞の療法的再プログラミング

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157071A1 (en) * 2001-05-31 2003-08-21 Wolfe M. Michael Treatment or replacement therapy using transgenic stem cells delivered to the gut
WO2007006862A2 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method and kit for detecting a risk of coronary heart disease
CN102002475A (zh) * 2010-03-10 2011-04-06 和泽生物科技有限公司 人脂肪成体干细胞的获取方法及该干细胞库的构建方法
CN102486475A (zh) * 2011-09-27 2012-06-06 臻景生物技术(上海)有限公司 一种自体脂肪干细胞抗衰老效果的评价体系

Also Published As

Publication number Publication date
CN102486475B (zh) 2015-12-02
CN102486475A (zh) 2012-06-06

Similar Documents

Publication Publication Date Title
US20190040361A1 (en) Brown fat cell compositions and methods
US20210260129A1 (en) Cell Expansion Methods and Therapeutic Compositions
CN105861430A (zh) 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用
Bhandari et al. The simplest method for in vitro β-cell production from human adult stem cells
CN110577931B (zh) 间断缺氧处理干细胞来源外泌体及在心肌组织中的应用
CN113136362B (zh) 一种囊泡及其应用
CN109929799B (zh) 人脐带间充质干细胞外泌体及其制备方法和应用
CN105132369B (zh) 一种将间充质干细胞转化为睾酮分泌细胞的诱导剂及诱导培养基
CN110352240A (zh) 围产期组织衍生的间充质干细胞:其制备方法和用途
WO2021147923A1 (zh) 一种囊泡及其应用
CN110403959B (zh) 间充质干细胞外泌体制剂及其应用
CN109481466A (zh) 使用胎盘间充质干细胞治疗卵巢早衰的方法和细胞制剂
CN102485885A (zh) 脂肪干细胞的分离方法和用途
CN103301154B (zh) 脐带间充质干细胞在制备治疗红斑狼疮的制剂中的用途
CN109652366A (zh) 用于治疗卵巢早衰的胎盘间充质干细胞制剂
WO2021219003A1 (zh) 一种脂肪来源干细胞制剂、制备方法及其应用
CN109674819A (zh) 胎盘间充质干细胞制剂及其治疗硬化病的用途
CN112029717B (zh) 无血清体外驯化培养人间充质干细胞
Taha et al. Adipose-derived stem/progenitor cells from lipoaspirates: A comparison between the Lipivage200-5 liposuction system and the Body-Jet liposuction system
CN103620023B (zh) 睾丸体细胞来源的多能干细胞、其制备方法以及包含其的治疗勃起功能障碍的药物组合物
Szaraz et al. Glucose withdrawal induces Endothelin 1 release with significant angiogenic effect from first trimester (FTM), but not term human umbilical cord perivascular cells (HUCPVC)
CN109646458A (zh) 使用胎盘间充质干细胞制剂治疗硬化病的方法
CN107557332B (zh) Cd29+人脐带源间充质干细胞及其在制备治疗高糖高脂环境下骨骼肌萎缩药物中的用途
WO2013044607A1 (zh) 一种自体脂肪干细胞抗衰老效果的评价体系
Pan et al. Development of a tree shrew metabolic syndrome model and use of umbilical cord mesenchymal stem cell transplantation for treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12837470

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12837470

Country of ref document: EP

Kind code of ref document: A1